Bluejay Diagnostics partners with Lovell Government Services to target US federal healthcare market
BJDX•Rollout depends on regulatory clearance
Rollout is contingent on FDA clearance or other regulatory authorization for Bluejay’s Symphony near-patient diagnostic platform.
Aims to expand access across major systems
The deal aims to build procurement access across major systems, including VHA with a proposed FY2026 budget of USD 165.1 billion.
Partnership targets federal healthcare procurement
Bluejay Diagnostics entered a distribution, co-marketing, strategic partnership with Lovell Government Services to target US federal healthcare customers.
Lovell becomes exclusive distributor for federal buys requiring or favoring SDVOSB status, including VA or DoD; non-exclusive for open-market tenders.
